Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Hims & Hers launched a $49 Wegovy-like drug, triggering Novo Nordisk’s legal threat over IP and sparking safety concerns.
Hims & Hers has launched a $49 version of the weight-loss drug Wegovy, prompting Novo Nordisk to threaten legal action over intellectual property rights.
The company's version is a compounded formulation, not an approved generic, raising concerns about safety and regulatory compliance.
The move has disrupted the market, causing Novo Nordisk's stock to drop.
58 Articles
Hims & Hers lanzó un medicamento similar a Wegovy por $49, lo que desencadenó la amenaza legal de Novo Nordisk sobre la propiedad intelectual y provocó preocupaciones de seguridad.